Britain and America have agreed to a landmark bilateral deal that will guarantee no import taxes on UK medicine products being sold in the American market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the NHS. This move guarantees that import taxes on these crucial exports will remain at zero for a timeframe of 36 months.
This development is in response to recent statements to dramatically increase duties on patented drug products, with increases mentioned as high as 100%.
"This deal between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and brings much-needed balance to transatlantic drug exports," a release noted.
Trade Impact
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the America, which is easily the largest destination for leading UK drugmakers.
Export figures reveal that in the one-year period prior to September, the UK shipped medicines valued at billions to the US. This amount made up 17.4% of British export trade in that timeframe.
"This deal secures employment, boosts capital expenditure and paves the way for the UK to emerge as a worldwide center for life sciences," a government official remarked.
Specific UK Commitments
The deal entails several notable changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it judges new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, refunds were more than 20%.
Recent Tensions
The pact takes place against a long-running row between the pharmaceutical industry and the British authorities over drug pricing and regulatory access.
The disagreement were intensified by arguments that US patients were charged significantly more for the same drugs than people in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been paused or scrapped, while major expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
